

ORDER NOW



For adults on maximally tolerated statins with TG ≥ 150 mg/dL and established CVD or diabetes and ≥ 2 CVD risk factors

The first and only FDA-approved medication for reducing CV risk^{1*}

Retail Fact Sheet for VASCEPA® (icosapent ethyl)

SUPPLIED AND MARKETING BY

Amarin Pharma Inc.

PRODUCT NAME

VASCEPA

GENERIC NAME

icosapent ethyl

PRODUCT WEBSITE

www.vascepahcp.com

PRODUCT INFORMATION (NDC)

1-gram capsules: 52937-001-20

0.5-gram capsules: 52937-003-40

DESCRIPTION

1-gram or 0.5-gram, amber-colored, liquid-filled, soft-gelatin capsules imprinted with VASCEPA

QUANTITY

Bottles of 120 1-gram capsules or

240 0.5-gram capsules

PRICE

For 120 1-gram capsules: \$330.98

For 240 0.5-gram capsules: \$387.24

WHOLESALE ORDERING INFORMATION

Please contact your wholesaler of choice to order VASCEPA.

CODES FOR WHOLESALE

ABC – AM21200

McKesson – AM24000

Cardinal – AM34000

PRODUCT EXPIRATION

See label for specific expiration dates.

PRESCRIPTION LEGEND

Prescription only.

STORAGE AND HANDLING REQUIREMENTS

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] Keep out of reach of children.

PRODUCT RETURNS

Please contact your wholesaler for any returns.

Commercially insured patients can pay as little as \$9 for a 90-day[†] supply with the VASCEPA Savings Card. Subject to eligibility. Restrictions apply.[†]

You can download the universal VASCEPA Savings Card at vascepahcp.com/savings[†]



^{*}Cardiovascular risk associated with events including myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization.

[†]Offer Restrictions: May not be used to obtain prescription drugs paid in part by Federal or State Programs including Medicare, Medicaid, Medicare Advantage, Medicare Part D, Tricare, VA. Most eligible, insured patients will pay as little as \$9 of their copay for either each month or a 90 day fill, with a maximum savings of up to \$150 per month or \$450 on a 90 day fill. Not for use by residents of VT, nor medical professionals licensed in VT. This offer is not valid for those patients under 18 years of age or patients whose plans do not permit use of a copay card. Void where prohibited by law, taxed, or restricted. Eligible patients include those who participate in commercial insurance, through a healthcare exchange, or pay cash. Offer good through December 31, 2020.

[†]Universal Pharmacy Card (UPC) may be applied for any eligible patient by entering all 4 codes.

INDICATIONS AND LIMITATIONS OF USE

- VASCEPA® (icosapent ethyl) is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease
- VASCEPA is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

IMPORTANT SAFETY INFORMATION

- VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components

Please see additional Important Safety Information for VASCEPA on the back and accompanying full Prescribing Information for VASCEPA or go to www.vascepahcp.com.

Vascepa®
(icosapent ethyl)



THE NEXT LEVEL OF HEART PROTECTION

Retail Fact Sheet for VASCEPA® (icosapent ethyl)

- ▶ The first and only highly purified, stable, single-entity preparation of icosapent ethyl (IPE)¹
- ▶ Significantly lowers TG levels *without increasing LDL-C*¹
- ▶ Reduces CV risk in adult patients with elevated triglyceride levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease¹
- ▶ VASCEPA has a well-established safety profile^{1,2}
- ▶ The daily dose of VASCEPA is 4 g per day taken as two 1-g or four 0.5-g capsules BID with food¹

Medical Information

For Medical Information, call 1-855-VASCEPA (827-2372) or e-mail amarinmi@druginfo.com.

IMPORTANT SAFETY INFORMATION (cont'd)

- VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter
- It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur
- VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin
- Common adverse reactions in the cardiovascular outcomes trial (incidence $\geq 3\%$ and $\geq 1\%$ more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%) and atrial fibrillation (5% vs 4%)
- Common adverse reactions in the hypertriglyceridemia trials (incidence $\geq 1\%$ more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%)
- Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088
- Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding

Please see accompanying full Prescribing Information for VASCEPA or go to www.vascepahcp.com.

References: 1. VASCEPA [package insert]. Bridgewater, NJ: Amarin Pharma, Inc.; 2019. 2. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, placebo-controlled, Randomized, double-blind, 12-week study with an open-label Extension [MARINE] trial). *Am J Cardiol*. 2011;108(5):682-690.

www.vascepahcp.com



VASCEPA is a registered trademark of the Amarin group of companies.

©2020 Amarin Pharma, Inc. Bridgewater, NJ 08807 All rights reserved. VAS-02424 01/20

Vascepa[®]
(icosapent ethyl)



THE NEXT LEVEL OF HEART PROTECTION